Haifa Kathrin A. A.
- Country
- Germany
- Department
- Department of Hematology and Internal Oncology
Research Overview
- Evaluation of INCA033989 Efficacy and Safety in Patients with Myelofibrosis or Essential Thrombocythemia within Myeloproliferative Neoplasms
- A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
- Phase 3 Randomized Open‑Label Study of Elritercept Versus Epoetin Alfa for Anemia in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndromes Requiring RBC Transfusions
Data & Insights
Has run more than one trial at 247 of 415 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in the study and treatment of myeloproliferative neoplasms, with particular emphasis on innovative therapeutic approaches for blood disorders.
- Myelofibrosis Management
- Essential Thrombocythemia Treatment
- Blood Cancer Research
Their research encompasses comprehensive investigation of novel therapeutic agents for hematologic malignancies.
Blood Disorders
Focused on advancing treatment options for patients with chronic blood disorders, particularly those affecting bone marrow function and blood cell production.
- Bone Marrow Disorders
- Blood Cell Production Abnormalities
- Thrombotic Disorders
The investigator explores therapeutic interventions targeting blood cell regulation and bone marrow function.
Clinical Innovation
Actively involved in evaluating novel therapeutic compounds for hematologic conditions, with a focus on patient safety and treatment efficacy.
- Targeted Therapy Development
- Treatment Safety Assessment
- Patient Response Evaluation
Their work contributes to the development of new treatment options for hematologic disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.